HRMY Q2 2021 Earnings — Harmony Biosciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

HRMYHarmony Biosciences Holdings, Inc.

$2B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$74M+94.2% YoY

Gross Profit

$61M82.8% margin

Operating Income

$23M31.6% margin

Net Income

$14M19.1% margin

EPS (Diluted)

$0.24

QoQ Revenue Growth

+23.7%

Cash Flow

Operating Cash Flow

$18M

Free Cash Flow

$18M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$360M

Total Liabilities

$233M

Stockholders' Equity

$127M

Cash & Equivalents

$160M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$74M	$38M	+94.2%
Gross Profit	$61M	$32M	+93.8%
Operating Income	$23M	$7M	+218.9%
Net Income	$14M	-$27,000	+52385.2%